Are there any drug interactions between cinnarizine, dimenhydrinate, and pregabalin?

Drug Interactions Between Cinnarizine, Dimenhydrinate, and Pregabalin

Yes, there is a clinically significant drug interaction: combining cinnarizine, dimenhydrinate, and pregabalin creates additive central nervous system (CNS) depression that increases risks of sedation, dizziness, cognitive impairment, and falls—particularly concerning in older adults.

Mechanism of Interaction

All three medications act as CNS depressants through different mechanisms:

• Cinnarizine and dimenhydrinate are both antihistamines with anticholinergic properties that cause sedation and impair mental alertness 1
• Pregabalin is a gabapentinoid that commonly produces dose-dependent dizziness and sedation 2, 3
• Pregabalin specifically demonstrates additive effects on cognitive and gross motor functioning when co-administered with other CNS-active drugs 3

Clinical Significance

The 2019 AGS Beers Criteria explicitly warns against concurrent use of three or more CNS-active drugs (including antiepileptics like pregabalin and antihistamines) due to increased fall risk in older adults 4. This combination represents exactly such a scenario.

Key risks include:

• Enhanced sedation beyond what each drug produces individually
• Impaired motor coordination and balance
• Increased fall risk (especially problematic given vertigo patients already have balance issues)
• Cognitive impairment and mental clouding 5
• Compounded dizziness (all three drugs list this as a common side effect)

Practical Management Recommendations

If this combination is being considered:

1. Avoid in older adults (≥65 years) whenever possible due to AGS Beers Criteria warnings 4

2. Start with the lowest possible doses if combination cannot be avoided:

   • Pregabalin: 25-50 mg/day initially (not standard 150 mg) 5
   • Use standard dosing for cinnarizine/dimenhydrinate fixed combination (20 mg/40 mg three times daily) 6, 7

3. Monitor intensively for:

   • Excessive sedation or somnolence
   • Falls or near-falls
   • Cognitive changes
   • Worsening dizziness beyond baseline vertigo

4. Adjust for renal impairment: Both pregabalin and antihistamines require dose reduction in renal dysfunction 2, 5

5. Warn patients explicitly about:

   • Not driving or operating machinery 1
   • Avoiding alcohol (further additive CNS depression) 1
   • Sitting/standing slowly to prevent falls

Alternative Approaches

Consider sequential rather than simultaneous therapy:

• Treat acute vertigo with cinnarizine/dimenhydrinate first (typically 4-6 weeks) 6, 7
• If neuropathic pain requires pregabalin, consider discontinuing antihistamines once vertigo improves
• The cinnarizine/dimenhydrinate combination is intended for short-term vertigo management, not chronic use 8

Special Populations

Elderly patients warrant particular caution because:

• Baseline increased sensitivity to anticholinergic effects 1
• Higher fall risk even without medications
• Pregabalin should start at lowest doses (25-50 mg/day) in this population 5
• Antihistamines may cause paradoxical excitation in some elderly patients 1

Bottom line: This three-drug combination is pharmacologically problematic due to additive CNS depression. Use only when benefits clearly outweigh risks, employ lowest effective doses, monitor closely for adverse effects, and avoid in older adults whenever possible per established guidelines 4.